# ScoreItem: ECG - Sokolow-Lyon (S V1 + R V5/V6)

**ID:** `019bf31d-2ef0-7c5b-bea0-13bf3f2a4fbb`
**FullName:** ECG - Sokolow-Lyon (S V1 + R V5/V6) (Exames - Imagem)
**Unit:** mm

**Preparation Metadata:**
- Quality Grade: **GOOD**
- Total Chunks: 30 de 14 artigos
- Avg Similarity: 0.526

---

## Contexto

Voc√™ √© um especialista em medicina funcional integrativa e est√° contribuindo com o **Escore Plenya** ‚Äî um escore completo de an√°lise de sa√∫de que avalia todos os aspectos da sa√∫de, performance e longevidade humana. Cada ScoreItem representa um par√¢metro cl√≠nico, laboratorial, gen√©tico, comportamental ou hist√≥rico que comp√µe esse escore.

Seu papel √© gerar conte√∫do cl√≠nico de alta qualidade para enriquecer cada par√¢metro do escore com relev√¢ncia cl√≠nica, orienta√ß√£o ao paciente e conduta pr√°tica.

**Regras inegoci√°veis:**
- Use **apenas** o conhecimento m√©dico real consolidado e os dados presentes nos chunks cient√≠ficos abaixo
- **N√£o alucine, n√£o invente** dados, estudos, estat√≠sticas ou refer√™ncias que n√£o estejam nos chunks ou no seu conhecimento m√©dico estabelecido
- Se um dado espec√≠fico n√£o constar nos chunks e n√£o for do seu conhecimento consolidado, **n√£o o inclua**
- Seja preciso: prefira omitir a inventar

## Instru√ß√£o

Com base nos chunks cient√≠ficos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `019bf31d-2ef0-7c5b-bea0-13bf3f2a4fbb`.**

```json
{
  "score_item_id": "019bf31d-2ef0-7c5b-bea0-13bf3f2a4fbb",
  "clinical_relevance": "Texto t√©cnico para m√©dicos (1000-5000 chars): defini√ß√£o fisiol√≥gica precisa, valores de refer√™ncia e interpreta√ß√£o, fisiopatologia resumida, dados epidemiol√≥gicos com n√∫meros concretos, estratifica√ß√£o de risco baseada em evid√™ncias.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que √© este par√¢metro sem jarg√µes, por que √© importante para a sa√∫de, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta cl√≠nica em Markdown (1000-5000 chars): investiga√ß√£o complementar necess√°ria, crit√©rios de encaminhamento a especialistas, interven√ß√µes baseadas em evid√™ncias. Use bullet points, se√ß√µes e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto cl√≠nico: 1-9 pts
- Alto impacto cl√≠nico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Crit√©rios: gravidade/mortalidade (40%), preval√™ncia (30%), intervencionabilidade (30%)

---

### Contexto Cient√≠fico

**ScoreItem:** ECG - Sokolow-Lyon (S V1 + R V5/V6) (Exames - Imagem)
**Unidade:** mm

**30 chunks de 14 artigos (avg similarity: 0.526)**

### Chunk 1/30
**Article:** Predictive value of electrocardiographic left ventricular hypertrophy in the general population: A meta-analysis (2020)
**Journal:** Journal of Electrocardiology
**Section:** abstract | **Similarity:** 0.665

This meta-analysis examined electrocardiographic left ventricular hypertrophy (LVH) as a predictor of adverse cardiac outcomes in 58,400 participants across 10 studies. The Sokolow-Lyon voltage, Cornell voltage, and Cornell product criteria showed comparable ability in predicting major adverse cardiovascular events (MACE), with risk ratios ranging from 1.56 to 1.70. The pooled risk ratio of MACE was 1.62 (95% CI 1.40-1.89) for Sokolow-Lyon voltage criteria. The pooled risk ratio of all-cause mortality was 1.47 (95% CI 1.10-1.97), and cardiovascular mortality was 1.38 (95% CI 1.19-1.60) for Sokolow-Lyon criteria. Cornell voltage demonstrated stronger predictive value for cardiovascular and all-cause mortality outcomes.

---

### Chunk 2/30
**Article:** Left ventricular hypertrophy determined by Sokolow-Lyon criteria: a different predictor in women than in men? (2006)
**Journal:** Journal of Human Hypertension
**Section:** abstract | **Similarity:** 0.624

This prospective study examined 3,338 women and 3,330 men with hypertension over 11.2 years to assess whether ECG left ventricular hypertrophy (LVH) by Sokolow-Lyon voltage criteria predicted cardiovascular outcomes differently by gender. Increasing voltage independently predicted CVD mortality in both men and women. The risk of stroke, coronary heart disease (CHD) and cardiovascular disease (CVD) mortality increased significantly for each quantitative 0.1 mV increase in baseline ECG voltage, in women within the range of 1.6-3.9% and in men 1.4-3.0%. Women tended to have a high risk of stroke mortality owing to LVH, while men demonstrated stronger associations between voltage and coronary heart disease mortality.

---

### Chunk 3/30
**Article:** Hipertens√£o Arterial Sist√™mica (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.543

causa secund√°ria identific√°vel.
**O diagn√≥stico e a classifica√ß√£o da hipertens√£o seguem limiares espec√≠ficos que variam conforme o m√©todo de medi√ß√£o, com est√°gios progressivos que orientam a terapia.**
- A press√£o arterial √© classificada como √≥tima (abaixo de 120/80 mmHg), normal (at√© 129/84 mmHg) e pr√©-hipertens√£o (130-139 / 85-89 mmHg).
- O diagn√≥stico de hipertens√£o √© estabelecido a partir de 14 por 9 mmHg em medi√ß√µes de consult√≥rio, aplic√°vel a indiv√≠duos com mais de 18 anos.
- Os est√°gios da hipertens√£o s√£o definidos como: Est√°gio 1 (a partir de 14/9), Est√°gio 2 (a partir de 16/10) e Est√°gio 3 (acima de 18/11).
- Para exames fora do consult√≥rio, os limiares s√£o mais baixos: 13 por 8 mmHg para o MAPA (24 horas) e 13 por 8,5 mmHg para o MRPA.

---

### Chunk 4/30
**Article:** Dislipidemias II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.540

dade, inatividade f√≠sica, press√£o arterial e dislipidemia.
- A inflama√ß√£o √© indicada por marcadores como a Prote√≠na C-Reativa (PCR), onde um valor de 5 j√° √© considerado elevado, e a Interleucina 6 (exemplo de paciente com 8.45).
- A resposta anti-inflamat√≥ria √© medida pela Interleucina 10, com um valor de corte de 3,5 (abaixo disso √© um risco) e um exemplo de paciente com 6.44.
- A sa√∫de do endot√©lio √© avaliada pelo √≥xido n√≠trico, que deve estar em 8.8; um paciente com 4.8 j√° apresenta disfun√ß√£o sist√™mica.
- A LDL oxidada √© um marcador cr√≠tico, com um limite saud√°vel de 133, enquanto pacientes de alto risco podem apresentar valores extremos, como 1000.
**Achados Adicionais**
- Existem cinco par√¢metros cl√°ssicos para definir a s√≠ndrome metab√≥lica.
- O alvo de LDL para pacientes de alto risco, segundo as diretrizes atuais, √© de 50.

---

### Chunk 5/30
**Article:** Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography (2015)
**Journal:** Journal of the American Society of Echocardiography
**Section:** abstract | **Similarity:** 0.538

Updated guidelines for echocardiographic assessment. Normal LVEF ‚â•54% in women by Simpson method. Sex-specific reference ranges are essential for accurate diagnosis of systolic dysfunction.

---

### Chunk 6/30
**Article:** Hipertens√£o Arterial Sist√™mica (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.536

*Classes Preferenciais:** IECA (Inibidores da Enzima Conversora de Angiotensina), BRA (Bloqueadores do Receptor de Angiotensina), diur√©ticos tiaz√≠dicos e bloqueadores do canal de c√°lcio. A combina√ß√£o entre eles √© a melhor estrat√©gia. A associa√ß√£o de IECA com BRA √© proibida.
*   **Hierarquia Terap√™utica:**
    1.  Mudan√ßa de estilo de vida.
    2.  IECA/BRA, bloqueador de canal de c√°lcio ou diur√©tico tiaz√≠dico.
    3.  Espironolactona (4¬™ op√ß√£o).
    4.  Betabloqueador (5¬™ op√ß√£o).
*   **Betabloqueadores:** N√£o s√£o mais primeira linha. T√™m menor prote√ß√£o cardiovascular, aumentam o risco de diabetes e causam efeitos adversos (disfun√ß√£o sexual, ganho de peso). S√£o considerados rem√©dios de exce√ß√£o.
*   **Metas Terap√™uticas:**
    *   **Alto risco:** Manter PA entre 120/70 e 130/80 mmHg.
    *   **Baixo/moderado risco e idosos h√≠gidos:** Manter PA at√© 140/90 mmHg.

---

### Chunk 7/30
**Article:** Aula Afonso Salgado - Sistema nervoso aut√¥nomo (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.536

ia√ß√£o descrito inclui:

- Exame realizado preferencialmente pela manh√£, em jejum, evitando a ingest√£o de medicamentos naquele momento (pois alteram a leitura).  
- Repeti√ß√£o do exame em **3 a 5 ocasi√µes** em condi√ß√µes semelhantes, para obter dados de ‚Äúpadr√£o ouro‚Äù (maior confiabilidade).  

A partir do ECG, softwares especializados analisam a VFC tanto no **dom√≠nio do tempo** quanto no **dom√≠nio da frequ√™ncia**:

- No dom√≠nio do tempo, o par√¢metro mais citado √© o **SDNN** (desvio padr√£o dos intervalos NN), que √© uma raiz quadrada aplicada √† distribui√ß√£o dos intervalos.  
- SDNN mais alto indica maior variabilidade; SDNN baixo indica rigidez do ritmo, associada a pior progn√≥stico.

No dom√≠nio da frequ√™ncia, embora Afonso n√£o detalhe numericamente, ele indica o uso de t√©cnicas matem√°ticas como:

- **R√°pida transformada de Fourier (FFT)**,  
- **wavelet transform**,  
- **ritmogramas** (conceito de origem russa).

---

### Chunk 8/30
**Article:** Exercise as medicine ‚Äì evidence for prescribing exercise as therapy in 26 different chronic diseases (2026)
**Journal:** Revista n√£o identificada
**Section:** results | **Similarity:** 0.535

diseasedurationandlowdensitylipoproteincholesterollevels.JAmCollCardiol
1996:28:573‚Äì579.50Pedersen&Saltin
	
	
Getulio Jos√© Mattos Do Amaral Filho - getfilho@yahoo.com.br - CPF: 034.983.039-88

CoakleyEH,RimmEB,ColditzG,KawachiI,WillettW.Predictorsofweightchangeinmen:resultsfrom
theHealthProfessionalsFollow-upStudy.IntJObesRelatMetabDisord1998:22:89‚Äì96.CoatsAJ,AdamopoulosS,MeyerTE,ConwayJ,SleightP.Effectsofphysicaltraininginchronicheartfailure.Lancet1990:335:63‚Äì66.CoatsAJ,AdamopoulosS,RadaelliA,McCanceA,MeyerTE,BernardiL,SoldaPL,DaveyP,OrmerodO,ForfarC.Controlledtrialofphysical
traininginchronicheartfailure.

---

### Chunk 9/30
**Article:** Confounders in Identification and Analysis of Inflammatory Biomarkers in Cardiovascular Diseases (2026)
**Journal:** Revista n√£o identificada
**Section:** results | **Similarity:** 0.534

atherosclerosis:Resultsfromaprospective,parallel-groupcohortstudy.Clin.Chim.Acta2015,447,16‚Äì22.[CrossRef]101.Hijazi,Z.;Lindahl,B.;Oldgren,J.;Andersson,U.;Lindb√§ck,J.;Granger,C.B.;Alexander,J.H.;Gersh,B.J.;Hanna,M.;Harjola,V.;etal.RepeatedMeasurementsofCardiacBiomarkersinAtrialFibrillationandValidationoftheABCStrokeScoreOverTime.J.Am.HeartAssoc.2017,6,e004851.[CrossRef]102.Abramson,J.L.;Lewis,C.;Murrah,N.V.;Anderson,G.T.;Vaccarino,V.RelationofC-ReactiveProteinandTumorNecrosisFactor-AlphatoAmbulatoryBloodPressureVariabilityinHealthyAdults.Am.J.Cardiol.2006,98,649‚Äì652.[CrossRef]103.Simundic,A.-M.;Kackov,S.;Miler,M.;Fraser,C.G.;Petersen,P.H.TermsandSymbolsUsedinStudiesonBiologicalVariation:TheNeedforHarmonization.Clin.Chem.2015,61,438‚Äì439.[CrossRef]
	
	
Getulio Jos√© Mattos Do Amaral Filho - getfilho@yahoo.com.br - CPF: 034.983.039-88

Biomolecules2021,11,1464
17of17
104.Khuseyinova,N.;Greven,S.;R√ºckerl,R.;Trischler,G.;Loewel,H.;Peters,A.;

---

### Chunk 10/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** discussion | **Similarity:** 0.530

from125to250pg/ml,whileforthoseover75years,itextendsfrom125to500pg/ml.Itiscrucialtoconductathoroughevaluationofpatientswithinthegreyzone,consideringfactorssuchasobesity,race-basedvariations,andongoingtreatment(asmanypatientswithahistory
ofhypertensionmayalreadybeondiuretics,renin‚Äìangiotensin
systeminhibitors,ormineralocorticoidreceptorantagonists).Intheoutpatientsetting,theextentofelevationinNPconcen-trationsatthetimeofheartfailurediagnosisiscloselylinkedtothe
riskofsubsequenthospitalizationandmortality.16Asaresult,therehasbeenasuggestiontoutilizeNT-proBNPconcentrationsatthe
timeofacommunity-basedheartfailurediagnosisasatriagingtooltoprioritizeaccesstoexpediteddiagnosticechocardiogra-phyandtosetupafollow-upplanforindividualswiththehighest
short-termriskofadverseevents.Theauthorsofthisconsensus
documentalignwiththeNICEguidelinesonchronicheartfailure,
whichrecommendacut-offvalueofNT-proBNP>2000pg/ml.40InananalysisofprimarycaredatafromEngland,anNT-proBNPvalue
of>2000pg/mlwasassociatedwi

---

### Chunk 11/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.527

N-terminalproB-typenatriureticpeptide;BSA,bodysurfacearea;SBP,systolicbloodpressure;DBP,diastolicbloodpressure;eGFR,estimatedglomelurarltrationrate;LAVi,leftatrialvolumeindex;e,earlydiastolictransmitralowvelocity;E‚Ä≤,earlydiastolicmitralannularvelocity;TAPSE,tricuspidannularplaneexcursion;PASP,pulmonaryarterialsystolicpressure;RVOT-AT,rightventricularoutowtractaccelerationtime;VO2peak,peakoxygenconsumption;NYHA,NewYorkHeartAssociation;AF,atrialbrillation;ACE-I,angiotensin-converting-enzymeinhibitors;ARBs,angiotensin-receptorblockers;MRA,mineralocorticoid-receptorantagonist;ICD,implantablecardioverter-debrillator;CRT,cardiacresynchronizationtherapy;IGF-1D,IGF-1deciency;DHEA-SD,DHEA-Sdeciency.

---

### Chunk 12/30
**Article:** Sex-Specific Thresholds of High-Sensitivity Troponin in Patients With Suspected Acute Coronary Syndrome (2019)
**Journal:** Journal of the American College of Cardiology
**Section:** results | **Similarity:** 0.523

gnostics,andSingulex.All
otherauthorshavereportedthattheyhavenorelationshipsrelevanttothecontentsofthispapertodisclose.ManuscriptreceivedJuly11,2019;revisedmanuscriptreceivedJuly25,2019,acceptedJuly28,2019.JACCVOL.74,NO.16,2019Leeetal.OCTOBER22,2019:2032‚Äì43Sex-SpecicThresholdsofhs-cTnI2033

internationalguidelinesinuseduringenrollment(9,10).Throughoutthedurationofthetrial,allsitesmeasuredcardiactroponinusingboththecTnIand
hs-cTnIassayssimultaneously.Duringthevalidation
phase,onlytheresultsofthecTnIassaywerere-portedtotheattendingclinician,whileduringtheimplementationphase,onlytheresultsofthehs-cTnIassaywerereported.ThecTnIassay(ARCHITECTSTATtroponinIassay;AbbottLaboratories,AbbottPark,Illinois)with
asinglediagnosticthresholdforwomenandmen
wasusedtoguideclinicaldecisionsduringthevali-
dationphase.Theinterassaycoefcientofvariationwas<10%at40ng/lat7sitesand50ng/lat3sites,andtheseconcentrationswereusedasthediagnostic
thresholdsduringthevalidationphase(11).Duringtheimplementationphase,a

---

### Chunk 13/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** results | **Similarity:** 0.522

50%Moderate< 100< 2.6Low< 115< 3.0Alarming levels:Suspected homozygous familial hypercholesterolaemia:In untreated individuals> 500> 13.0In treated individuals> 300> 7.8Suspected heterozygous familial hypercholesterolaemia> 190> 4.9Unit conversion: [mg/dl] √ó 0.026 = [mmol/l].less, as with the use of other formulas, the accu-racy of non-HDL-C calculation depends on the bi-ological and analytical variability of TC and HDL-C concentrations. However, the biological variability 
of HDL-C levels is much lower than that of other lipid parameters, especially TG. In addition, HDL-C concentrations are much lower than the TC levels, which minimises their eÔ¨Äect on changes in calcu-lated non-HDL-C concentrations.Reporting of resultsAlongside the calculated non-HDL-C level, a¬†laboratory report should include information on 

Arch Med Sci 2, March / 2024 369the desirable (target) values with regard to cardio-vascular risk (Table VI).

---

### Chunk 14/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.521

(mm/mmHg)0.63¬±0.290.53¬±0.220.68¬±0.320.008Pericardialeffusion14(15.20%)7(23.30%)7(10.93%)0.11
VO2peak(ml*kg1*min1)(n=67)20.61¬±4.7018.89¬±4.9221.31¬±4.920.03NYHAclassII66(70.21%)21(70.00%)45(70.31%)0.98III23(24.46%)7(23.33%)16(25.00%)0.87
IV5(5.33%)2(6.67%)3(4.69%)0.65Aetiology(ischaemic)27(28.7%)17(56.7%)10(15.6%)0.01Yearofdisease5[2‚Äì10.75]4[1‚Äì9.75]7[2.75‚Äì12]0.1AF11(22.4%)4(13.33%)7(10.90%)0.73
Beta-blockers66(91.7%)24(72.00%)42(65.60%)0.15
ACE-I31(43.1%)12(40.00%)19(29.70%)0.22ARBs26(36.1%)9(30.00%)17(26.60%)0.72MRA26(36.1%)8(26.70%)18(28.12%)0.88
ICD26(36.6%)8(26.66%)18(28.10%)0.88
CRT10(14.1%)1(3.33%)9(14.10%)0.15IGF-1D50(53.2%)16(53.3%)34(53.1%)0.98DHEA-SD73(77.7%)29(97.7%)44(68.7%)0.01
TypeIIdiabetes26(27.7%)6(20%)20(31.2)0.37Abbreviations:TD,testosteronedeciency;NTproBNP,N-terminalproB-typenatriureticpeptide;BSA,bodysurfacearea;SBP,systolicbloodpressure;DBP,diastolicbloodpressure;eGFR,estimatedglomelurarltrationrate;LAVi,leftatrialvolumeindex;e,earlydiastolictransmit

---

### Chunk 15/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** discussion | **Similarity:** 0.514

sensus
documentalignwiththeNICEguidelinesonchronicheartfailure,
whichrecommendacut-offvalueofNT-proBNP>2000pg/ml.40InananalysisofprimarycaredatafromEngland,anNT-proBNPvalue
of>2000pg/mlwasassociatedwithamorethantwo-foldhigherriskofheartfailurehospitalizationand50%higherriskofmortalityascomparedwithanNT-proBNPof400‚Äì2000pg/ml.47Wesug-gestthat,irrespectiveofageandsex,patientswithanNT-proBNP
>2000pg/mlshouldbeprioritizedforechocardiographyandclini-calevaluationwithin2weeksofdiagnosis(Figure2).NT-proBNPinasymptomaticpatientswithriskfactors:heart
stressVariousriskfactors,suchashypertension,atheroscleroticcardio-vasculardisease,diabetes,obesity,andothers,contributetoanincreasedsusceptibilitytothedevelopmentofheartfailure.Intheabsenceofsymptomsofheartfailure,patientswithriskfactorsmay
exhibiteitherhearthealthorheartstress.Hearthealthrefersto
individualswhohaveastructurallynormalheartandnormalplasma
concentrationsofNPsandtroponins.¬©2023EuropeanSocietyofCardiology.

---

### Chunk 16/30
**Article:** Sex-Specific Thresholds of High-Sensitivity Troponin in Patients With Suspected Acute Coronary Syndrome (2019)
**Journal:** Journal of the American College of Cardiology
**Section:** results | **Similarity:** 0.514

638(45)2,472(50)1,084(52)1,388(48)2,166(40)862(42)1,304(39)Calcium-channelblocker1,977(19)921(19)397(19)524(18)1,056(19)412(20)644(19)Nicorandil645(6)303(6)149(7)154(5)342(6)174(8)168(5)
Ivabradine146(1)68(1)25(1)43(1)78(1)33(1)45(1)
Spironolactone450(4)201(4)82(4)119(4)249(4)113(5)136(4)Electrocardiographicresults¬ßNormal2,672(34)1,366(36)513(36)853(36)1,306(32)479(34)827(30)
Myocardialischemia2,510(32)1,023(27)342(24)681(28)1,487(36)445(32)1,042(38)ST-segmentelevation998(13)329(9)90(6)239(10)669(16)174(12)495(18)ST-segmentdepression1,328(17)583(16)226(16)357(15)745(18)234(17)511(18)
T-waveinversion1,277(16)640(17)252(17)388(16)637(15)232(16)405(15)Physiologicalparameters¬ßHeartrate,beats/min8626882788278826842685258326Systolicbloodpressure,mmHg13929141301402914130137281362813728GRACEriskscore14338147361483414738140391393814040HematologicandclinicalchemistrymeasurementsHemoglobin,g/l13125125241242412623137251362513725eGFR,ml/min47164616471646164915491

---

### Chunk 17/30
**Article:** Hipertens√£o Arterial Sist√™mica (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.513

tens√£o Est√°gio 1:** 140-159 / 90-99 mmHg.
        *   **Hipertens√£o Est√°gio 2:** 160-179 / 100-109 mmHg.
        *   **Hipertens√£o Est√°gio 3:** ‚â• 180/110 mmHg.
### 3. Tratamento N√£o Farmacol√≥gico: A Base da Terapia
*   **Princ√≠pio Fundamental:** A mudan√ßa no estilo de vida √© recomendada para TODOS os est√°gios de press√£o arterial, desde o diagn√≥stico.
*   **Principais Interven√ß√µes:**
    *   **Controle de Peso:** Cada 1 kg perdido reduz a PA em 1 mmHg.
    *   **Dieta Saud√°vel:** Recomenda-se uma dieta anti-inflamat√≥ria e low-carb, que aborda a resist√™ncia insul√≠nica. Pode reduzir a PA em 3-5 mmHg.
    *   **Atividade F√≠sica:** 150 minutos de atividade aer√≥bica/semana podem reduzir a PA em 5-7 mmHg.
    *   **Redu√ß√£o do √Ålcool:** Contribui para a diminui√ß√£o da press√£o.
    *   O potencial combinado dessas mudan√ßas pode reduzir a press√£o em 30 a 40 mmHg.
*   **A Pol√™mica do S√≥dio vs.

---

### Chunk 18/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** other | **Similarity:** 0.513

l/min/1.73 m2])Very high Cardiovascular disease documented clinically or by imaging examinations; diabetes mellitus with 
organ damage3 or other major risk factors4,5, early onset type 1 diabetes mellitus lasting > 20 years; chronic kidney disease with eGFR < 30 ml/min/1.73 m2; familial hypercholesterolaemia with cardiovas-cular disease or another major risk factor5; risk ‚â• 10% and ‚â§ 20% according to Pol-SCORE/very high risk according to SCORE2 or SCORE-2-OP for gender and ageHighSigniÔ¨Åcantly elevated single risk factor, especially TC > 310 mg/dl (> 8 mmol/l), LDL-C > 190 mg/dl  (> 4.9 mmol/l), or blood pressure ‚â• 180/110 mm Hg; familial hypercholesterolaemia without other risk factors; diabetes mellitus without organ damage (regardless of duration)6; chronic kidney disease with eGFR 30¬ñ59 ml/min/1.73 m2; risk ‚â• 5% and < 10% according to Pol-SCORE /high risk according to SCORE2 or SCORE-2-OP for gender and ageModerateRisk < 5% according to Pol-SCORE/low and moderate risk acc

---

### Chunk 19/30
**Article:** Exercise as medicine ‚Äì evidence for prescribing exercise as therapy in 26 different chronic diseases (2026)
**Journal:** Revista n√£o identificada
**Section:** introduction | **Similarity:** 0.511

ontraindicationsThefollowingcontraindicationsareinagreementwithaEuropeanWorkingGroup(Gianuzzi&
Tavazzi2001).ÔøΩAcuteCHU(AMIorunstableangina),untilthe
conditionhasbeenstableforatleast5daysÔøΩDyspneaatrestÔøΩPericarditis,myocarditis,endocarditisÔøΩSymptomaticaorticstenosisÔøΩSeverehypertension.Thereisnoestablished,docu-
mentedborderlinebloodpressurevaluedeemedto
bethecut-offpointforincreasedrisk.Generallyit
isrecommendedthatdemandingphysicalexercise
beavoidedinthecaseofsystolicBP>180ordias-
tolicBP>105mmHgÔøΩFeverÔøΩSeriousnon-cardiacdiseaseHeartfailureBackgroundHeartfailureisaconditionwheretheheartisunabletopumpsufÔ¨ÅcientlytomaintainbloodÔ¨Çowtomeetthemetabolicneedsoftheperipheraltissue(Braun-
wald&Libby,2008).Heartfailureisaclinicalsyn-
dromewithsymptomssuchasÔ¨Çuidretention,
breathlessness,orexcessivetirednesswhenrestingor
exercising,andwithobjectivesymptomsofreduced
systolicfunctionoftheleftventricleatrest.Asymptomaticleftventriculardysfunctionisoftentheprecursorofthissyndrome.Sympt

---

### Chunk 20/30
**Article:** Sex-Specific Thresholds of High-Sensitivity Troponin in Patients With Suspected Acute Coronary Syndrome (2019)
**Journal:** Journal of the American College of Cardiology
**Section:** results | **Similarity:** 0.510

dline).Patientsaregroupedaccordingtowhethermyocardialinjurywaspresent(red)orabsent(gray).Pairedlog-ranktestresultsarep¬º0.40forwomenwithmyocardialinjuryandp¬º0.08forwomenwithoutmyocardialinjury.JACCVOL.74,NO.16,2019Leeetal.OCTOBER22,2019:2032‚Äì43Sex-SpecicThresholdsofhs-cTnI2039

infarctioninwomenandmen(15).Theimpactofsex-specicthresholdsonthediagnosisofmyocardialinfarctionhasbeenevaluatedinanumberofobser-vationalstudieswithdivergentndings(7,16‚Äì20).Mostofthesestudiesenrolledselectedpatientswith
acutecoronarysyndrome,ofwhomthemajoritywere
men.Furthermore,sex-specicthresholdswerenotusedtoguideclinicalcareorsubsequentinvestiga-
tionforcoronaryarterydisease.Here,weimple-
mentedsex-specicthresholdsintoroutineclinicalcareinarandomizedcontrolledtrialandevaluatedtheirimpactinconsecutivepatientspresentingwith
suspectedacutecoronarysyndrome.Wefoundthat
useofsex-specicthresholdsidentiedproportion-atelymorewomen,suchthattheoverallpercentages
ofwomenandmenidentiedashavingmyocardialinjury

---

### Chunk 21/30
**Article:** Hipertens√£o Arterial Sist√™mica (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.508

a PA sist√≥lica em 5.6 mmHg e a diast√≥lica em 2.8 mmHg. Potencializa o efeito de anti-hipertensivos. A forma taurato √© a mais indicada.
*   **C√∫rcuma Longa:** Uso por mais de 12 semanas mostrou redu√ß√£o m√©dia de 8 mmHg na PA sist√≥lica.
*   **Outros:** Pot√°ssio (com cautela), quercetina, arginina, cacau, resveratrol e piquenogenol tamb√©m podem auxiliar.
*   **Abordagem Integrativa:** A suplementa√ß√£o melhora vias metab√≥licas e inflamat√≥rias, auxiliando no controle da press√£o. √â crucial saber quando usar medica√ß√£o se as metas n√£o forem atingidas apenas com estilo de vida e suplementos.
## ‚ùì Perguntas
- [Inserir Pergunta/Confus√£o]
## üìö Tarefas
- [ ] 1. Para pacientes com suspeita de hipertens√£o, solicitar MAPA ou MRPA para um diagn√≥stico preciso.
- [ ] 2. Rastrear ativamente causas de hipertens√£o secund√°ria, como apneia do sono (polissonografia) e disfun√ß√µes da tireoide (TSH).
- [ ] 3.

---

### Chunk 22/30
**Article:** Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018 (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.507

ricanCollegeofCardiology/AmericanHeartAssociation
TaskForceonPracticeGuidelines.2013AHA/ACC
GuidelineonLifestyleManagementtoReduce
CardiovascularRisk.JAmCollCardiol.2014;63(25,ptB):2960-2984.doi:10.1016/j.jacc.2013.11.00323.YancyCW,JessupM,BozkurtB,etal;AmericanCollegeofCardiologyFoundation;AmericanHeart
AssociationTaskForceonPracticeGuidelines.2013
ACCF/AHAGuidelinefortheManagementofHeart
Failure.JAmCollCardiol.2013;62(16):e147-e239.doi:10.1016/j.jacc.2013.05.01924.O‚ÄôGaraPT,KushnerFG,AscheimDD,etal.2013ACCF/AHAGuidelinefortheManagementof
ST-ElevationMyocardialInfarction:areportofthe
AmericanCollegeofCardiologyFoundation/
AmericanHeartAssociationTaskForceonPractice
Guidelines.JAmCollCardiol.2013;61(4):e78-e140.doi:10.1016/j.jacc.2012.11.01925.FihnSD,GardinJM,AbramsJ,etal;AmericanCollegeofCardiologyFoundation;AmericanHeart
AssociationTaskForceonPracticeGuidelines;AmericanCollegeofPhysicians;AmericanAssociationforThoracicSurgery;Preventive
CardiovascularNursesAssociation;Societyfor
Car

---

### Chunk 23/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.507

fortheman-
agementofheartfailure:Areportof
theAmericanCollegeofCardiologyFoundation/AmericanHeartAssociationtaskforceonpracticeguidelines.JAmCollCardiol.2013;62:e147‚Äìe239.3.BealeAL,MeyerP,MarwickTH,LamCSP,KayeDM.Sexdifferencesincardio-vascularpathophysiology:Whywomen
areoverrepresentedinheartfailurewith
preservedejectionfraction.Circulation.2018;138:198‚Äì205.4.ShahKS,XuH,MatsouakaRA,BhattDL,HeidenreichPA,HernandezAF,Devore
AD,YancyCW,FonarowGC.Heartfail-urewithpreserved,borderline,andre-ducedejectionfraction:5-yearout-
comes.JAmCollCardiol.2017;70:2476‚Äì2486.5.HsichEM,Grau-SepulvedaMV,HernandezAF,PetersonED,Schwamm
LH,BhattDL,FonarowGC.Sex
differencesinin-hospitalmortalityinacutedecompensatedheartfailurewithreducedandpreservedejection
fraction.AmHeartJ.2012;163:430‚Äì437.e3.6.CittadiniA,SalzanoA,IacovielloM,TriggianiV,RengoG,CacciatoreF,
MaielloC,LimongelliG,MasaroneD,
PerticoneF,CimellaroA,PerroneFilardiP,PaolilloS,ManciniA,VolterraniM,VrizO,CastelloR,PassantinoA,Campo
M,ModestiPA

---

### Chunk 24/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.506

ceptorantagonist;NT-proBNP,N-terminal
pro-B-typenatriureticpeptide;RASi,renin‚Äìangiotensinsysteminhibitor.thesecut-points,itisindicativeoflikelyheartfailure,andarrangingechocardiographywithin6weeksisadvised(Figure2).Complexcut-pointschemesthatincorporatemultiplecomor-biditiesinadditiontoagecanbetakenintoconsideration,especially
iftheycanbeintegratedintoelectronichealthrecordsthattrig-
geranalarmwhenNT-proBNPconcentrationsexceedspeciedthresholds.Theseshouldincludeage-andsex-specicNT-proBNPcut-pointsforthediagnosisofHFwithadjustmentsforrenal
dysfunction,atrialbrillationorutterincludingventricularrate
onthebaselinerestingelectrocardiogram(ECG)andbodymass
index(BMI).Table1showssuggestedNT-proBNPcut-offsstrat-iedbyageandgenderfornon-obesepatientswithoutkidneyfailureandatrialbrillation/utteronbaselineECG.46Thefol-lowingsuggestedmodicationsforcomorbidconditionsarebased
moreonexpertopinionratherthanonstrongevidenceandshould
berenedasmoreinformationbecomesavailable.WheneGFRis<30ml/min

---

### Chunk 25/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.505

calPracticeGuidelines.JAmCollCardiol2022;79:1757‚Äì1780.https://doi.org/10.1016/j.jacc.2021.12.0114.Revuelta-L√≥pezE,BarallatJ,Cserk√≥ov√°A,G√°lvez-Mont√≥nC,JaffeAS,JanuzziJL,etal.Pre-analyticalconsiderationsinbiomarkerresearch:Focusoncardiovasculardisease.ClinChemLabMed.2021;59:1747‚Äì1760.5.Pop-BusuiR,JanuzziJL,BruemmerD,ButaliaS,GreenJB,HortonWB,etal.Heartfailure:Anunderappreciatedcomplicationofdiabetes.Aconsensusreportofthe
AmericanDiabetesAssociation.DiabetesCare2022;45:1670‚Äì1690.https://doi.org/10.2337/dci22-00146.BozkurtB,CoatsAJS,TsutsuiH,AbdelhamidCM,AdamopoulosS,AlbertN,etal.Universaldenitionandclassicationofheartfailure:AreportoftheHeartFailureSocietyofAmerica,HeartFailureAssociationoftheEuropean
SocietyofCardiology,JapaneseHeartFailureSocietyandWritingCommittee
oftheUniversalDenitionofHeartFailure:EndorsedbytheCanadianHeart
FailureSociety,HeartFailureAssociationofIndia,CardiacSocietyofAustralia
andNewZealand,andChineseHeartFailureAssociation.EurJHeartFail2021;23:352‚Äì

---

### Chunk 26/30
**Article:** Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018 (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.504

heTaskForce
fortheDiagnosisandManagementofHypertrophic
CardiomyopathyoftheEuropeanSocietyof
Cardiology(ESC).EurHeartJ.2014;35(39):2733-2779.doi:10.1093/eurheartj/ehu28461.WarnesCA,WilliamsRG,BashoreTM,etal.ACC/AHA2008GuidelinesfortheManagementof
AdultsWithCongenitalHeartDisease:areportof
theAmericanCollegeofCardiology/AmericanHeart
AssociationTaskForceonPracticeGuidelines
(WritingCommitteetoDevelopGuidelinesonthe
ManagementofAdultsWithCongenitalHeart
Disease)developedincollaborationwiththe
AmericanSocietyofEchocardiography,Heart
RhythmSociety,InternationalSocietyforAdult
CongenitalHeartDisease,Societyfor
CardiovascularAngiographyandInterventions,
andSocietyofThoracicSurgeons.JAmCollCardiol.2008;52(23):e143-e263.doi:10.1016/j.jacc.2008.10.00162.MoscaL,BankaCL,BenjaminEJ,etal;ExpertPanel/WritingGroup;AmericanHeartAssociation;
AmericanAcademyofFamilyPhysicians;American
CollegeofObstetriciansandGynecologists;
AmericanCollegeofCardiologyFoundation;Society
ofThoracicSurgeons;AmericanMedicalW

---

### Chunk 27/30
**Article:** Dislipdemia (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.502

enta online que usa par√¢metros cl√≠nicos e o escore de c√°lcio para estimar o risco cardiovascular em 10 anos. Possui limita√ß√µes por n√£o incluir marcadores da medicina integrativa.
*   **Uso Criterioso de Estatinas:**
    - **Preven√ß√£o Prim√°ria (baixo risco):** O uso √© controverso e muitas vezes desnecess√°rio, pois o NNT √© muito alto e os riscos de efeitos adversos podem superar os benef√≠cios.
    - **Preven√ß√£o Secund√°ria (p√≥s-evento):** O uso √© justificado pelo baixo NNT e pelos **efeitos pleotr√≥picos** da estatina, que incluem:
        - Redu√ß√£o da inflama√ß√£o e melhora da fun√ß√£o endotelial.
        - Diminui√ß√£o da oxida√ß√£o dentro da placa.
        - Estabiliza√ß√£o da placa, tornando-a menos propensa √† ruptura.
*   **Exames Cl√≠nicos Avan√ßados:**
    - **Subfracionamento das part√≠culas de LDL e HDL:** Avalia o tamanho e a quantidade das part√≠culas.
    - **Anti-LDL Oxidado:** Mede a taxa de oxida√ß√£o do colesterol.

---

### Chunk 28/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.501

¬±SDMean¬±SDMean¬±SDAge(years)66.18¬±10.2668.93¬±9.74564.89¬±10.3250.12NTproBNP(pg/ml)2597.05¬±4093.042794.47¬±3380.142504.52¬±4409.550.72
BSA(m2)1.70¬±0.161.68¬±0.11.71¬±0.190.34SBP(mmHg)123.29¬±17.82121.32¬±16.86124.24¬±18.370.53DBP(mmHg)75.46¬±12.3975.05¬±9.5175.65¬±13.650.85
eGFR(ml/min)68.61¬±34.2854.27¬±23.0275.55¬±36.760.001
Haemoglobin(g/dl)12.85¬±1.5312.50¬±1.2113.01¬±1.650.13Albumin(%)56.8¬±5.256.6¬±7.756.9¬±3.70.9Testosterone(ng/dl)48.80¬±61.8613.60¬±6.6362.55¬±68.16<0.001Ejectionfraction(%)33.81¬±6.4633.20¬±7.6634.10¬±5.850.53
LAVi(ml/m2)49.46¬±25.5755.51¬±30.2446.63¬±22.770.17e/E‚Ä≤14.68¬±9.9613.04¬±4.9512.53¬±6.400.16TAPSE(mm)18.82¬±4.5117.78¬±4.2619.31¬±4.560.12
PASP(mmHg)34.38¬±13.2537.69¬±13.7232.84¬±12.840.98
RVOT-AT(ms)103.27¬±36.47112.11¬±34.7497.15¬±37.730.35TAPSE/PASP(mm/mmHg)0.63¬±0.290.53¬±0.220.68¬±0.320.008Pericardialeffusion14(15.20%)7(23.30%)7(10.93%)0.11
VO2peak(ml*kg1*min1)(n=67)20.61¬±4.7018.89¬±4.9221.31¬±4.920.03NYHAclassII66(70.21%)21(70.00%)45(70.31

---

### Chunk 29/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.500

herauthorshavenothing
todisclose.References1.McDonaghTA,MetraM,AdamoM,GardnerRS,BaumbachA,B√∂hmM,etal.;ESCScienticDocumentGroup.2021ESCGuidelinesforthediagnosisandtreatmentofacuteandchronicheartfailure:DevelopedbytheTaskForcefor
thediagnosisandtreatmentofacuteandchronicheartfailureoftheEuropean
SocietyofCardiology(ESC).WiththespecialcontributionoftheHeartFailure
Association(HFA)oftheESC.EurJHeartFail2022;24:4‚Äì131.https://doi.org/10.1002/ejhf.23332.Guidelinesforthediagnosisofheartfailure.TheTaskForceonHeartFailureoftheEuropeanSocietyofCardiology.EurHeartJ1995;16:741‚Äì751.3.HeidenreichPA,BozkurtB,AguilarD,AllenLA,ByunJJ,ColvinMM,etal.AHA/ACC/HFSAGuidelineforthemanagementofheartfailure:Executive
summary:AreportoftheAmericanCollegeofCardiology/AmericanHeart
AssociationJointCommitteeonClinicalPracticeGuidelines.JAmCollCardiol2022;79:1757‚Äì1780.https://doi.org/10.1016/j.jacc.2021.12.0114.Revuelta-L√≥pezE,BarallatJ,Cserk√≥ov√°A,G√°lvez-Mont√≥nC,JaffeAS,JanuzziJL,etal.Pre-analyticalconsid

---

### Chunk 30/30
**Article:** Dislipdemia (2024)
**Journal:** Pos Graduacao MFI
**Section:** discussion | **Similarity:** 0.500

vida e identificar fatores de risco para inflama√ß√£o e disfun√ß√£o endotelial (dieta, estresse, sedentarismo).
- [ ] 2. Utilizar a calculadora MESA Risk para determinar o risco cardiovascular dos pacientes e considerar a solicita√ß√£o do Escore de C√°lcio Coronariano antes de prescrever estatinas em preven√ß√£o prim√°ria.
- [ ] 3. Ao avaliar o risco cardiovascular, solicitar exames avan√ßados como a rela√ß√£o ApoB/ApoA, subpart√≠culas de lipoprote√≠nas e anti-LDL oxidado para uma an√°lise mais aprofundada.
- [ ] 4. Em pacientes de preven√ß√£o prim√°ria, mesmo com colesterol alto, priorizar mudan√ßas no estilo de vida antes de considerar o uso de estatinas.
- [ ] 5. Reservar o uso de estatinas principalmente para pacientes em preven√ß√£o secund√°ria ou de alt√≠ssimo risco, focando nos seus efeitos pleotr√≥picos.
- [ ] 6.

---

